BMO Positive on Fate Therapeutics (FATE) Following Adaptive NK Cell Therapy-Focused ASH Dinner

BMO Capital analyst Do Kim weighed in on Fate Therapeutics (NASDAQ: FATE) attending the company's ASH event focused on its modified adaptive memory NK cell therapy, FATE-NK100.

Kim commented, "We believe NK cell mediated treatment could be among the best subclasses of immuno-oncology, given its tumor-specific cytotoxicity, but milder safety profile versus T-cell based therapies. NK100 preclinical studies showed greater potency compared to unmodified NK cell treatments, which addresses the key limitation of NK cells. We expect NK100 to start Phase I in early 2017, with successful progress representing upside to our and Street estimates."

The firm maintained an Outperform rating and price target of $4.00 on FATE.

For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.

Shares of Fate Therapeutics closed at $3.11 yesterday.

You May Also Be Interested In

• Intermediate Capital Group (ICP:LN) (ICGUF) PT Raised to GBP22.50 at Citi
• Donnelley Financial Solutions (DFIN) PT Raised to $72 at B.Riley
• Teledyne (TDY) PT Lowered to $455 at Needham